Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
Nicola GökbugetNicolas BoisselSabina ChiarettiHervé DombretMichael DoubekAdele K FieldingRobin FoàSebastian GiebelDieter HoelzerMathilde M Hunault-BergerDavid I MarksGiovanni MartinelliOliver Gerhard OttmannAnita RijneveldPhilippe RousselotJosep-María RiberaRenato BassanPublished in: Blood (2024)
Working groups of the European LeukemiaNet have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different clinical and biological subgroups and the knowledge on disease biology and therapeutic options is increasing exponentially. The European Working Group for Adult ALL has therefore summarized the current state of the art and provided comprehensive consensus recommendations for diagnostic approaches, biologic and clinical characterization, prognostic factors, and risk stratification as well as definitions of endpoints and outcomes. Aspects of treatment, management of subgroups and specific situations, aftercare, and supportive care are covered in a separate publication. The present recommendation intends to provide guidance for the initial management of adult patients with ALL and to define principles as a basis for future collaborative research.
Keyphrases
- prognostic factors
- clinical practice
- acute lymphoblastic leukemia
- healthcare
- quality improvement
- rheumatoid arthritis
- palliative care
- systematic review
- type diabetes
- randomized controlled trial
- allogeneic hematopoietic stem cell transplantation
- skeletal muscle
- metabolic syndrome
- pain management
- weight loss
- acute myeloid leukemia
- combination therapy
- replacement therapy
- chronic pain
- clinical evaluation